Detalles de la búsqueda
1.
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Mol Cell;
71(4): 606-620.e7, 2018 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30118680
2.
Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy.
J Magn Reson Imaging;
2024 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38294179
3.
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Oncologist;
28(10): 845-855, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37318349
4.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.
Breast Cancer Res Treat;
199(3): 457-469, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37061619
5.
Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.
Mod Pathol;
35(5): 601-608, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34839351
6.
Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.
J Magn Reson Imaging;
56(6): 1901-1909, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35499264
7.
Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer.
Cancer;
127(16): 2880-2887, 2021 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33878210
8.
Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.
Clin Immunol;
225: 108679, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33485895
9.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
N Engl J Med;
379(8): 753-763, 2018 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30110579
10.
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).
Breast Cancer Res Treat;
185(1): 1-12, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32920733
11.
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Invest New Drugs;
39(2): 509-515, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32984932
12.
Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.
J Magn Reson Imaging;
54(1): 251-260, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33586845
13.
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw;
19(1): 77-102, 2021 01 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33406487
14.
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Oncologist;
25(3): e439-e450, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162822
15.
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Breast Cancer Res Treat;
181(2): 391-401, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32323103
16.
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
J Natl Compr Canc Netw;
18(4): 380-391, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32259785
17.
Initial safety analysis of a randomized phase II trial of nelipepimut-Sâ¯+â¯GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
Clin Immunol;
201: 48-54, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30817999
18.
Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
Curr Opin Oncol;
31(3): 247-255, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30789866
19.
BRCA mutations in women with inflammatory breast cancer.
Cancer;
124(3): 466-474, 2018 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29044548
20.
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
Clin Immunol;
195: 28-35, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30025819